 SOUTH SAN FRANCISCO, Calif., March 08, 2022 GLOBE NEWSWIRE -- Tempest Therapeutics, Inc. Nasdaq: TPST, a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced two poster presentations at the 2022 American Association for Cancer Research AACR virtual annual meeting taking place April 8-13, 2022. The presentations contain new preclinical data for two of Tempests small molecule programs, TPST-1495 clinical-stage dual EP24 antagonist and TREX1 preclinical STING agonist. 